SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Mutation R131H

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 Association of FC-Gamma Receptor Genotypes With Response and Clinical Benefit With Addition of Rituximab to CHOP Chemotherapy in Patients With Follicular Lymphoma (FL)

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and tissue samples from patients with follicular lymphoma treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone.

NCT00933127 Lymphoma Genetic: DNA analysis Genetic: polymerase chain reaction Genetic: polymorphism analysis Other: laboratory biomarker analysis
MeSH:Lymphoma Lymphoma, Follicular

OUTLINE: Genomic DNA extracted from paired samples of serum and formalin-fixed paraffin-embedded tissue is analyzed for R131H polymorphism in Fcγ receptor IIa and V158F polymorphism in Fcγ receptor IIIa by TaqMan-based assay. --- R131H ---

Primary Outcomes

Measure: Association of Fc-gamma (Fcγ) receptor genotypes with overall and/or progression-free survival and clinical response

Time: retrospectively

Measure: Novel polymorphisms in Fcγ receptors for predictive and prognostic significance

Time: retrospectively

HPO Nodes